Global Recombinant Human Coagulation VIIa 麻豆原创 Growth 2025-2031

Publication ID:

LPI04250192

Publication Date:

April 17, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Human Coagulation VIIa market size is predicted to grow from US$ 1265 million in 2025 to US$ 1585 million in 2031; it is expected to grow at a CAGR of 3.8% from 2025 to 2031.
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
Coagulation Factor VIIa, recombinant is a coagulation factor indicated for:
Treatment of bleeding episodes and perioperative management in adults and children with Hemophilia or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann鈥檚 thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
Treatment of bleeding episodes and perioperative management in adults with acquired haemophilia.
Drivers of the Recombinant Human Coagulation Factor VIIa (rFVIIa) 麻豆原创:
Rising Prevalence of Hemophilia and Bleeding Disorders: Recombinant Factor VIIa is primarily used in treating hemophilia, especially in patients with inhibitors to Factor VIII or IX. The growing global incidence of hemophilia and other bleeding disorders is a major driver of market demand.
Advancements in Recombinant Technology: Ongoing improvements in biotechnology have led to the development of safer and more effective recombinant coagulation products. These advancements reduce the risk of bloodborne pathogen transmission, increasing their adoption over plasma-derived alternatives.
Increased Use in Trauma and Surgery: Recombinant Factor VIIa is also used in managing severe bleeding during trauma and surgical procedures, further expanding its clinical applications and boosting demand, particularly in emergency care settings.
Rising Adoption in Off-Label Uses: While its primary indication is for hemophilia, rFVIIa is increasingly being used off-label to manage uncontrolled bleeding in non-hemophiliac patients, particularly in critical care and trauma settings. This broadens its potential market.
Favorable Reimbursement Policies in Developed Regions: In regions like North America and Europe, the availability of comprehensive insurance and reimbursement for advanced therapies like rFVIIa makes these treatments more accessible to patients, supporting market growth.
Challenges of the Recombinant Human Coagulation Factor VIIa (rFVIIa) 麻豆原创:
High Cost of Treatment: Recombinant Factor VIIa therapy is expensive, which can limit access, especially in low-income countries and regions without robust healthcare funding or insurance coverage.
Potential for Off-Label Use Concerns: Despite its increasing use in off-label applications, concerns about the safety and efficacy of rFVIIa in non-hemophilia patients have led to caution in its broader application. Regulatory scrutiny on off-label use may impact market expansion.
Limited Awareness and Access in Developing Regions: In many developing countries, awareness of recombinant therapies for hemophilia is limited, and access to advanced treatments is constrained by inadequate healthcare infrastructure and funding.
Competition from Alternative Therapies: Emerging gene therapies, extended half-life clotting factors, and other innovative treatments for hemophilia may compete with or reduce the demand for rFVIIa in the future. These newer therapies promise more long-term efficacy or convenience.
Regulatory Challenges: The stringent regulatory approval process for biologics, along with the ongoing need for post-market surveillance, can slow down the introduction of new products or indications, impacting the pace of market growth.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.
The 鈥淩ecombinant Human Coagulation VIIa Industry Forecast鈥� looks at past sales and reviews total world Recombinant Human Coagulation VIIa sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Coagulation VIIa sales for 2025 through 2031. With Recombinant Human Coagulation VIIa sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Coagulation VIIa industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Coagulation VIIa landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Coagulation VIIa portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Human Coagulation VIIa market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Coagulation VIIa and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Coagulation VIIa.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Coagulation VIIa market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Prefilled Syringe
Vial
Segmentation by Application:
Congenital Hemophilia
Acquired Hemophilia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Human Coagulation VIIa market?
What factors are driving Recombinant Human Coagulation VIIa market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Coagulation VIIa market opportunities vary by end market size?
How does Recombinant Human Coagulation VIIa break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Recombinant Human Coagulation VIIa Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Recombinant Human Coagulation VIIa by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Recombinant Human Coagulation VIIa by Country/Region, 2020, 2024 & 2031
2.2 Recombinant Human Coagulation VIIa Segment by Type
2.2.1 Prefilled Syringe
2.2.2 Vial
2.3 Recombinant Human Coagulation VIIa Sales by Type
2.3.1 Global Recombinant Human Coagulation VIIa Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Recombinant Human Coagulation VIIa Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Recombinant Human Coagulation VIIa Sale Price by Type (2020-2025)
2.4 Recombinant Human Coagulation VIIa Segment by Application
2.4.1 Congenital Hemophilia
2.4.2 Acquired Hemophilia
2.4.3 Others
2.5 Recombinant Human Coagulation VIIa Sales by Application
2.5.1 Global Recombinant Human Coagulation VIIa Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Recombinant Human Coagulation VIIa Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Recombinant Human Coagulation VIIa Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Recombinant Human Coagulation VIIa Breakdown Data by Company
3.1.1 Global Recombinant Human Coagulation VIIa Annual Sales by Company (2020-2025)
3.1.2 Global Recombinant Human Coagulation VIIa Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Recombinant Human Coagulation VIIa Annual Revenue by Company (2020-2025)
3.2.1 Global Recombinant Human Coagulation VIIa Revenue by Company (2020-2025)
3.2.2 Global Recombinant Human Coagulation VIIa Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Recombinant Human Coagulation VIIa Sale Price by Company
3.4 Key Manufacturers Recombinant Human Coagulation VIIa Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human Coagulation VIIa Product Location Distribution
3.4.2 Players Recombinant Human Coagulation VIIa Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Recombinant Human Coagulation VIIa by Geographic Region
4.1 World Historic Recombinant Human Coagulation VIIa 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Recombinant Human Coagulation VIIa Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Recombinant Human Coagulation VIIa Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Recombinant Human Coagulation VIIa 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Recombinant Human Coagulation VIIa Annual Sales by Country/Region (2020-2025)
4.2.2 Global Recombinant Human Coagulation VIIa Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Human Coagulation VIIa Sales Growth
4.4 APAC Recombinant Human Coagulation VIIa Sales Growth
4.5 Europe Recombinant Human Coagulation VIIa Sales Growth
4.6 Middle East & Africa Recombinant Human Coagulation VIIa Sales Growth
5 Americas
5.1 Americas Recombinant Human Coagulation VIIa Sales by Country
5.1.1 Americas Recombinant Human Coagulation VIIa Sales by Country (2020-2025)
5.1.2 Americas Recombinant Human Coagulation VIIa Revenue by Country (2020-2025)
5.2 Americas Recombinant Human Coagulation VIIa Sales by Type (2020-2025)
5.3 Americas Recombinant Human Coagulation VIIa Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Coagulation VIIa Sales by Region
6.1.1 APAC Recombinant Human Coagulation VIIa Sales by Region (2020-2025)
6.1.2 APAC Recombinant Human Coagulation VIIa Revenue by Region (2020-2025)
6.2 APAC Recombinant Human Coagulation VIIa Sales by Type (2020-2025)
6.3 APAC Recombinant Human Coagulation VIIa Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Human Coagulation VIIa by Country
7.1.1 Europe Recombinant Human Coagulation VIIa Sales by Country (2020-2025)
7.1.2 Europe Recombinant Human Coagulation VIIa Revenue by Country (2020-2025)
7.2 Europe Recombinant Human Coagulation VIIa Sales by Type (2020-2025)
7.3 Europe Recombinant Human Coagulation VIIa Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Human Coagulation VIIa by Country
8.1.1 Middle East & Africa Recombinant Human Coagulation VIIa Sales by Country (2020-2025)
8.1.2 Middle East & Africa Recombinant Human Coagulation VIIa Revenue by Country (2020-2025)
8.2 Middle East & Africa Recombinant Human Coagulation VIIa Sales by Type (2020-2025)
8.3 Middle East & Africa Recombinant Human Coagulation VIIa Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Coagulation VIIa
10.3 Manufacturing Process Analysis of Recombinant Human Coagulation VIIa
10.4 Industry Chain Structure of Recombinant Human Coagulation VIIa
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human Coagulation VIIa Distributors
11.3 Recombinant Human Coagulation VIIa Customer
12 World Forecast Review for Recombinant Human Coagulation VIIa by Geographic Region
12.1 Global Recombinant Human Coagulation VIIa 麻豆原创 Size Forecast by Region
12.1.1 Global Recombinant Human Coagulation VIIa Forecast by Region (2026-2031)
12.1.2 Global Recombinant Human Coagulation VIIa Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Recombinant Human Coagulation VIIa Forecast by Type (2026-2031)
12.7 Global Recombinant Human Coagulation VIIa Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Recombinant Human Coagulation VIIa Product Portfolios and Specifications
13.1.3 Novo Nordisk Recombinant Human Coagulation VIIa Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 LFB SA HEMA Biologics
13.2.1 LFB SA HEMA Biologics Company Information
13.2.2 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product Portfolios and Specifications
13.2.3 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 LFB SA HEMA Biologics Main Business Overview
13.2.5 LFB SA HEMA Biologics Latest Developments
13.3 AryoGen Pharmed
13.3.1 AryoGen Pharmed Company Information
13.3.2 AryoGen Pharmed Recombinant Human Coagulation VIIa Product Portfolios and Specifications
13.3.3 AryoGen Pharmed Recombinant Human Coagulation VIIa Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AryoGen Pharmed Main Business Overview
13.3.5 AryoGen Pharmed Latest Developments
13.4 GENERIUM
13.4.1 GENERIUM Company Information
13.4.2 GENERIUM Recombinant Human Coagulation VIIa Product Portfolios and Specifications
13.4.3 GENERIUM Recombinant Human Coagulation VIIa Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 GENERIUM Main Business Overview
13.4.5 GENERIUM Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.